Hypersensitivity Reaction and Rapid Drug Desensitization with Chemotherapeutics: A Tertiary Reference Center Experiences
- 13 July 2023
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (9) , 849-855
Abstract
Introduction: Chemotherapy drugs have been in our lives for a long time, and all agents have the potential to develop hypersensitivity. Rapid drug desensitization is an option when hypersensitivity develops. The aim of this study was to examine the characteristics, diagnostic processes, and treatment results of patients with chemotherapeutic agent hypersensitivity who applied to our tertiary reference center. Methods: Patients who applied to our tertiary allergy outpatient clinic between January 2016 and September 2022 due to chemotherapy-induced drug hypersensitivity were examined. Demographic data of the patients, cancer diagnoses, chemotherapy regimens, skin tests, premedication scheme, desensitization cycle were evaluated. We applied a 16-step desensitization in patients with index reaction anaphylaxis or positive skin tests. If the index reaction was not anaphylaxis or skin tests were negative, we applied a 12-step desensitization. If the prick test with chemotherapeutic drugs was negative especially with taxanes, premedication was administered. We used the montelukast, cetirizine, and methylprednisolone for premedication. Results: Fifty-one patients were evaluated; 35 (68.6%) were female. The most common malignancy was colorectal cancer in 17 (33.3%) patients. The most common agent responsible for hypersensitivity was oxaliplatin in 17 (33.3%) patients, followed by paclitaxel in 13 (25.4%). When the symptoms of immediate reaction to chemotherapeutic drugs were analyzed as described in the EAACI position paper, only skin and mucosal involvement was seen in 24 (46.8%) patients; only respiratory system involvement or back pain was seen in 3 (6.2%) patients; multisystem involvement meeting the criteria for anaphylaxis was seen in 24 (47%) patients. Skin test was positive in 17 (56.6%) of 30 patients who developed a reaction with platin. Prolonged anaphylaxis was developed in 1 patient, and desensitization was not performed again. Fifty of 51 patients were able to receive the target chemotherapy dose by desensitization. In total, a 172-step desensitization was applied to 51 patients. Conclusion: If completing the cycle is considered a treatment success, this was achieved in 98% (50/51) patients with rapid drug desensitization. This gives us the opportunity to use first-line chemotherapy agents.Keywords
This publication has 19 references indexed in Scilit:
- Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal AntibodiesCurrent Pharmaceutical Design, 2017
- Anaphylaxis—a practice parameter update 2015Annals of Allergy, Asthma & Immunology, 2015
- Presentation and Diagnosis of Hypersensitivity to Platinum DrugsCurrent Allergy and Asthma Reports, 2015
- Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitizationAllergy, 2015
- Skin test concentrations for systemically administered drugs – anENDA/EAACIDrug Allergy Interest Group position paperAllergy, 2013
- Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitizationCancer Immunology, Immunotherapy, 2012
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelLeukemia & Lymphoma, 2011
- The Complex Clinical Picture of Presumably Allergic Side Effects to Cytostatic Drugs: Symptoms, Pathomechanism, Reexposure, and DesensitizationMedical Clinics of North America, 2010
- Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 casesJournal of Allergy and Clinical Immunology, 2008
- Hypersensitivity reactions related to oxaliplatin (OHP)British Journal of Cancer, 2003